NANOBIOTIX Provides Third Quarter 2024 Update and Progress on Nanotherapeutics Platforms

Core Insights - Nanobiotix is advancing its NBTXR3 program, with a key step being the transfer of sponsorship for the global Phase 3 NANORAY-312 study to Janssen, which is crucial for potential regulatory submission [1][3] - The company has strengthened its Supervisory Board by adding industry experts to support long-term growth strategies [1][4] - Upcoming updates on clinical studies for pancreatic and lung cancers are expected in Q4 2024 and H1 2025, respectively [1][5] Operational Highlights - The sponsorship transfer of NANORAY-312 for head and neck cancer is underway, with Janssen taking over in the U.S. and plans for global regions to follow [3] - The company anticipates interim analysis for NANORAY-312 in H1 2026 after the required patient events [5] - Updated dose escalation data for pancreatic cancer from the collaboration with MD Anderson is expected in Q4 2024 [5] Financial Updates - As of September 30, 2024, Nanobiotix reported €53.2 million in cash and cash equivalents, providing a cash runway into Q4 2025 [6][7] Product Development - The Curadigm program, which focuses on next-generation nanoparticle-based therapies, is expected to provide updates in Q4 2024 [6] - NBTXR3, a novel oncology product, is designed to induce tumor cell death when activated by radiotherapy, with potential applications across various solid tumors [8][9] Strategic Collaborations - Nanobiotix has engaged in a collaboration with MD Anderson to evaluate NBTXR3 across multiple tumor types and therapeutic combinations [10] - The company has a license agreement with Janssen for the global co-development and commercialization of NBTXR3 [10] Company Overview - Nanobiotix is a late-stage clinical biotechnology company focused on innovative therapeutic approaches to improve treatment outcomes for cancer patients [11][12] - The company is headquartered in Paris, France, and is listed on Euronext Paris and Nasdaq [12]